Candidate risk factors and mechanisms for tolvaptan-induced liver injury are identified using a collaborative cross approach

Toxicological Sciences

Volumn 156, Issue 2, 2017, Pages 438-454

  Mosedale, Merrie ^a,b   Kim, Yunjung ^a,c   Brock, William J ^d,e   Roth, Sharin E ^d   Wiltshire, Tim ^b,c   Eaddy, J Scott ^a,b   Keele, Gregory R ^c   Corty, Robert W ^c   Xie, Yuying ^c,f   Valdar, William ^a,b   Watkins, Paul B ^a,b  

^a UNIVERSITY OF NORTH CAROLINA   (United States)

^b University of North Carolina   (United States)

^c UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^d OTSUKA PHARMACEUTICAL DEVELOPMENT AND COMMERCIALIZATION INC   (United States)

^e Brock Scientific Consulting   (United States)

^f MICHIGAN STATE UNIVERSITY   (United States)

Author keywords

Collaborative cross; Drug induced liver injury; Precision medicine; Tolvaptan; Toxicogenomics

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; BILE ACID; BILIRUBIN; EPOXIDE HYDROLASE; EPOXIDE HYDROLASE 2; INTERFERON REGULATORY FACTOR 3; MITOCHONDRIAL FISSION FACTOR; PROTEIN; SECRETORY LEUKOCYTE PROTEINASE INHIBITOR; TOLVAPTAN; UNCLASSIFIED DRUG; BENZAZEPINE DERIVATIVE; BIOLOGICAL MARKER; TRANSCRIPTOME;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILE ACID METABOLISM; BILIRUBIN BLOOD LEVEL; CONTROLLED STUDY; DRUG MEGADOSE; GENE EXPRESSION; GENE EXPRESSION PROFILING; GENETIC RISK; GENETIC SUSCEPTIBILITY; HAPLOTYPE; IMMUNE RESPONSE; MOUSE; NONHUMAN; OXIDATIVE STRESS; QUANTITATIVE TRAIT LOCUS MAPPING; RISK ASSESSMENT; RISK FACTOR; TOXIC HEPATITIS; TOXICOGENETICS; TRANSCRIPTOMICS; ANIMAL; BLOOD; DRUG EFFECTS; GENETICS; IMMUNOLOGY; INBRED MOUSE STRAIN; INNATE IMMUNITY; LIVER FUNCTION TEST; SPECIES DIFFERENCE;

ANIMALS; BENZAZEPINES; BIOMARKERS; CHEMICAL AND DRUG INDUCED LIVER INJURY; IMMUNITY, INNATE; LIVER FUNCTION TESTS; MICE, INBRED STRAINS; OXIDATIVE STRESS; RISK FACTORS; SPECIES SPECIFICITY; TOXICOGENETICS; TRANSCRIPTOME;

EID: 85017181739     PISSN: 10966080     EISSN: 10960929     Source Type: Journal    
DOI: 10.1093/toxsci/kfw269     Document Type: Article

References (58)

1. Antoniades, C. G. Khamri, W. Abeles, R. D. Taams, L. S. Triantafyllou, E. Possamai, L. A. Bernsmeier, C. Mitry, R. R. O'Brien, A. Gilroy, D. et al. (2014). Secretory leukocyte protease inhibitor: A pivotal mediator of anti-inflammatory responses in acetaminophen-induced acute liver failure. Hepatology 59, 1564-1576.
2. Bates, D.Mächler, M. Bolker, B. and Walker, S. (2015). Fitting linear mixed-effects models using lme4. J. Stat. Softw. 67(1), 1-48.
3. Benjamini, Y. and Hochberg, Y. (1995). Controlling the false discovery rate: A practical and powerful approach to multiple testing. J. R Stat. Soc. 57, 289-300.
4. Burkholder, T. Foltz, C. Karlsson, E. Linton, C. G. and Smith, J. M. (2012). Health evaluation of experimental laboratory mice. Curr. Protoc. Mouse Biol. 2, 145-165.
5. Collaborative Cross Consortium. (2012). The genome architecture of the collaborative cross mouse genetic reference population. Genetics 190, 389-401.
6. Court, M. H. Peter, I. Hazarika, S. Vasiadi, M. Greenblatt, D. J. and Lee, W. (2013). Candidate gene polymorphisms in patients with acetaminophen-induced acute liver failure. Drug Metabolism and Disposition
7. Dudbridge, F. and Koeleman, B. P. C. (2004). Efficient Computation of significance levels for multiple associations in large studies of correlated data, including genomewide association studies. Am. J. Hum. Genet. 75, 424-435.
8. Fagerberg, L. Hallström, B. M. Oksvold, P. Kampf, C. Djureinovic, D. Odeberg, J. Habuka, M. Tahmasebpoor, S. Danielsson, A. Edlund, K. et al. (2014). Analysis of the human tissue-specific expression by genome-wide integration of transcriptomics and antibody-based proteomics. Mol. Cell. Proteomics 13, 397-406.
9. Festing, M. F. W. (2010). Inbred strains should replace outbred stocks in toxicology, safety testing, and drug development. Toxicol. Pathol. 38, 681-690.
10. Fu, C. P. Welsh, C. E. Villena, FPMd. and McMillan, L. (2012). Inferring ancestry in admixed populations using microarray probe intensities. In Proceedings of the ACM Conference on Bioinformatics, Computational Biology and Biomedicine, Orlando, Florida, ACM, pp. 105-112.
11. Gandre-Babbe, S. and van der Bliek, A. M. (2008). The novel tailanchored membrane protein Mff controls mitochondrial and peroxisomal fission in mammalian cells. Mol. Biol. Cell 19, 2402-2412.
12. Glasgow, A. M. A. Small, D. M. Scott, A. McLean, D. T. Camper, N. Hamid, U. Hegarty, S. Parekh, D. O'Kane, C. Lundy, F. T. et al. (2015). A role for whey acidic protein four-disulfide-core 12 (WFDC12) in the regulation of the inflammatory response in the lung. Thorax 70, 426-432.
13. Guo, L. Li, S. Zhao, Y. Qian, P. Ji, F. Qian, L. Wu, X. and Qian, G. (2015). silencing angiopoietin-like protein 4 (ANGPTL4) protects against lipopolysaccharide-induced acute lung injury via regulating SIRT1/NF-kB pathway. J. Cell. Physiol. 230, 2390-2402.
14. Halekoh, U. and Højsgaard, S. (2014). A Kenward-Roger approximation and parametric bootstrap methods for tests in linear mixed models - The R package pbkrtest. J. Stat. Softw. 59(9), 1-32.
15. Harrill, A. H. DeSmet, K. D. Wolf, K. K. Bridges, A. S. Eaddy, J. S. Kurtz, C. L. Hall, J. E. Paine, M. F. Tidwell, R. R. and Watkins, P. B. (2012). A mouse diversity panel approach reveals the potential for clinical kidney injury due to DB289 not predicted by classical rodent models. Toxicol. Sci. 130, 416-426.
16. Harrill, A. H. Watkins, P. B. Su, S. Ross, P. K. Harbourt, D. E. Stylianou, I. M. Boorman, G. A. Russo, M. W. Sackler, R. S. Harris, S. C. et al. (2009). Mouse population-guided resequencing reveals that variants in CD44 contribute to acetaminophen-induced liver injury in humans. Genome Res. 19, 1507-1515.
17. Herwartz, C. Castillo-Juárez, P. Schröder, L. Barron, B. L. and Steger, G. (2015). The transcription factor ZNF395 is required for the maximal hypoxic induction of proinflammatory cytokines in U87-MG cells. Mediators Inflamm. 2015, 804264.
18. Irizarry, R. A. Hobbs, B. Collin, F. Beazer-Barclay, Y. D. Antonellis, K. J. Scherf, U. and Speed, T. P. (2003). Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 4, 249-264.
19. Kaplowitz, N. (2005). Idiosyncratic drug hepatotoxicity. Nat. Rev. Drug Discov. 4, 489-499.
20. Keane, T. M. Goodstadt, L. Danecek, P. White, M. A. Wong, K. Yalcin, B. Heger, A. Agam, A. Slater, G. Goodson, M. et al. (2011). Mouse genomic variation and its effect on phenotypes and gene regulation. Nature 477, 289-294.
21. Kelada, S. N. P. Carpenter, D. E. Aylor, D. L. Chines, P. Rutledge, H. Chesler, E. J. Churchill, G. A. Pardo-Manuel de Villena, F. Schwartz, D. A. and Collins, F. S. (2014). Integrative genetic analysis of allergic inflammation in the murine lung. Am. J. Respir. Cell Mol. Biol. 51, 436-445.
22. Kroh, E. M. Parkin, R. K. Mitchell, P. S. and Tewari, M. (2010). Analysis of circulating microRNA biomarkers in plasma and serum using quantitative reverse transcription-PCR (qRTPCR). Methods 50, 298-301.
23. Laifenfeld, D. Qiu, L. Swiss, R. Park, J. Macoritto, M. Will, Y. Younis, H. S. and Lawton, M. (2014). Utilization of causal reasoning of hepatic gene expression in rats to identify molecular pathways of idiosyncratic drug-induced liver injury. Toxicol. Sci. 137, 234-248.
24. Leone, A. Nie, A. Brandon Parker, J. Sawant, S. Piechta, L. A. Kelley, M. F. Mark Kao, L. Jim Proctor, S. Verheyen, G. Johnson, M. D. et al. (2014). Oxidative stress/reactive metabolite gene expression signature in rat liver detects idiosyncratic hepatotoxicants. Toxicol. Appl. Pharmacol. 275, 189-197.
25. Li, J. and Uetrecht, J. P. (2010). The danger hypothesis applied to idiosyncratic drug reactions. Handb Exp Pharmacol 493-509.
26. Li, X. Magenheimer, B. S. Xia, S. Johnson, T. Wallace, D. P. Calvet, J. P. and Li, R. (2008). A tumor necrosis factor-[alpha]- mediated pathway promoting autosomal dominant polycystic kidney disease. Nat Med 14, 863-868.
27. Loi, P. Yuan, Q. Torres, D. Delbauve, S. Laute, M. A. Lalmand, M. C. Pétein, M. Goriely, S. Goldman, M. and Flamand, V. (2013). Interferon regulatory factor 3 deficiency leads to interleukin-17-mediated liver ischemia-reperfusion injury. Hepatology 57, 351-361.
28. Lyle, C. and McCormick, F. (2010). Integrin avb5 is a primary receptor for adenovirus in CAR-negative cells. Virol. J. 7, 148-148.
29. Miyazaki, T. Fujiki, H. Yamamura, Y. Nakamura, S. and Mori, T. (2007). Tolvaptan, an orally active vasopressin V2-receptor antagonist-pharmacology and clinical trials. Cardiovasc. Drug Rev. 25, 1-13.
30. Morgan, A. P. and Welsh, C. E. (2015). Informatics resources for the Collaborative Cross and related mouse populations. Mamm. Genome 26, 521-539.
31. Mosedale, M. and Watkins, P. B. (2016). Drug-induced liver injury: Advances in mechanistic understanding that will inform risk management. Clin. Pharmacol. Ther. doi:10.1002/ cpt.564.
32. Mosedale, M. Wu, H. Kurtz, C. L. Schmidt, S. P. Adkins, K. and Harrill, A. H. (2014). Dysregulation of protein degradation pathways may mediate the liver injury and phospholipidosis associated with a cationic amphiphilic antibiotic drug. Toxicol. Appl. Pharmacol.
33. Mott, R. Talbot, C. J. Turri, M. G. Collins, A. C. and Flint, J. (2000). A method for fine mapping quantitative trait loci in outbred animal stocks. Proc. Natl. Acad. Sci. U.S.A. 97, 12649-12654.
34. Muller, A. M. Jun, E. Conlon, H. and Sadiq, S. A. (2012). Inhibition of SLPI ameliorates disease activity in experimental autoimmune encephalomyelitis. BMC Neurosci. 13, 30.
35. Munoz-Garrido, P. Marin, J. J. G. Perugorria, M. J. Urribarri, A. D. Erice, O. Sáez, E. Uriz, M. Sarvide, S. Portu, A. Concepcion, A. R. et al. (2015). Ursodeoxycholic acid inhibits hepatic cystogenesis in experimental models of polycystic liver disease. J. Hepatol. 63, 952-961.
36. Ni, M. Xu, T. Wang, Y. He, Y. Zhou, Q. Huang, C. Meng, X. and Li, J. (2015). Inhibition of IRF3 expression reduces TGF-b1- induced proliferation of hepatic stellate cells. J. Physiol. Biochem. 72, 9-23.
37. Odaka, C. Mizuochi, T. Yang, J. and Ding, A. (2003). Murine Macrophages produce secretory leukocyte protease inhibitor during clearance of apoptotic cells: Implications for resolution of the inflammatory response. J. Immunol. 171, 1507-1514.
38. Oguro, A. Koyama, C. Xu, J. and Imaoka, S. (2014). A cellular stress response (CSR) that interacts with NADPH-P450 reductase (NPR) is a new regulator of hypoxic response. Biochem. Biophys. Res. Commun. 445, 43-47.
39. Oi, A. Morishita, K. Awogi, T. Ozaki, A. Umezato, M. Fujita, S. Hosoki, E. Morimoto, H. Ishiharada, N. Ishiyama, H. et al. (2011). Nonclinical safety profile of tolvaptan. Cardiovasc. Drugs Ther. 25(Suppl 1), S91-S99.
40. Phillippi, J. Xie, Y. Miller, D. R. Bell, T. A. Zhang, Z. Lenarcic, A. B. Aylor, D. L. Krovi, S. H. Threadgill, D. W. Pardo-Manuel de Villena, F. et al. (2014). Using the emerging Collaborative Cross to probe the immune system. Genes Immun. 15, 38-46.
41. Reeves, E. P. Banville, N. Ryan, D. M. O'Reilly, N. Bergin, D. A. Pohl, K. Molloy, K. McElvaney, O. J. Alsaleh, K. Aljorfi, A. et al. (2013). Intracellular secretory leukoprotease inhibitor modulates inositol 1,4,5-triphosphate generation and exerts an anti-inflammatory effect on neutrophils of individuals with cystic fibrosis and chronic obstructive pulmonary disease. BioMed Res. Int. 2013, 560141.
42. Rockman, M. V. and Kruglyak, L. (2006). Genetics of global gene expression. Nat. Rev. Genet. 7, 862-872.
43. Rutledge, H. Aylor, D. L. Carpenter, D. E. Peck, B. C. Chines, P. Ostrowski, L. E. Chesler, E. J. Churchill, G. A. de Villena, F. P. M. and Kelada, S. N. P. (2014). Genetic regulation of Zfp30, CXCL1, and neutrophilic inflammation in murine lung. Genetics 198, 735-745.
44. Schuck, R. N. Zha, W. Edin, M. L. Gruzdev, A. Vendrov, K. C. Miller, T. M. Xu, Z. Lih, F. B. DeGraff, L. M. Tomer, K. B. et al. (2014). The cytochrome P450 epoxygenase pathway regulates the hepatic inflammatory response in fatty liver disease. PLoS One 9, e110162.
45. Sen, Ś. and Churchill, G. A. (2001). A statistical framework for quantitative trait mapping. Genetics 159, 371-387.
46. Slizgi, J. R. Lu, Y. Brouwer, K. R. St. Claire, R. L. Freeman, K. M. Pan, M. Brock, W. J. and Brouwer, K. L. R. (2016). Inhibition of human hepatic bile acid transporters by tolvaptan and metabolites: contributing factors to drug-induced liver injury? Toxicol. Sci. 149(1), 237-250.
47. Svenson, K. L. Gatti, D. M. Valdar, W. Welsh, C. E. Cheng, R. Chesler, E. J. Palmer, A. A. McMillan, L. and Churchill, G. A. (2012). High-resolution genetic mapping using the mouse diversity outbred population. Genetics 190, 437-447.
48. Torres, V. E. Chapman, A. B. Devuyst, O. Gansevoort, R. T. Grantham, J. J. Higashihara, E. Perrone, R. D. Krasa, H. B. Ouyang, J. and Czerwiec, F. S. (2012). Tolvaptan in patients with autosomal dominant polycystic kidney disease. N. Engl. J. Med. 367, 2407-2418.
49. Vered, K. Durrant, C.Mott, R. and Iraqi, F. A. (2014). Susceptibility to klebsiella pneumonaie infection in collaborative cross mice is a complex trait controlled by at least three loci acting at different time points. BMC Genomics 15, 865.
50. Visscher, P. M. Thompson, R. and Haley, C. S. (1996). Confidence intervals in QTL mapping by bootstrapping. Genetics 143, 1013-1020.
51. Watkins, P.B. Lewis, J.H. Kaplowitz, N. Alpers, D. Blais, J. Smotzer, D. Krasa, H. Ouyang, J. Torres, V. Czerwiec, F. et al. (2015). Clinical pattern of tolvaptan-associated liver injury in subjects with autosomal dominant polycystic kidney disease: Analysis of clinical trials database. Drug Saf. 38, 1103-1113.
52. Williams, S. E. Brown, T. I. Roghanian, A. and Sallenave, J. M. (2006). SLPI and elafin: one glove, many fingers. Clin. Sci. (Lond) 110, 21-35.
53. Woodhead, J. L. Brock, W. J. Roth, S. E. Shoaf, S. E. Brouwer, K. L. R. Church, R. Grammatopoulos, T. N. Stiles, L. Siler, S. Q. Howell, B. A. et al. (2016). Application of a mechanisticmodel to evaluate putative mechanisms of tolvaptan drug-induced liver injury and identify patient susceptibility factors. Toxicol. Sci. doi:10.1093/toxsci/kfw193.
54. Woods, L. C. S. Holl, K. L. Oreper, D. Xie, Y. Tsaih, S. W. and Valdar, W. (2012). Fine-mapping diabetes-related traits, including insulin resistance, in heterogeneous stock rats. Physiol. Genomics 44, 1013-1026.
55. Wu, Y. Beland, F. A. Chen, S. Liu, F. Guo, L. and Fang, J. L. (2015). Mechanisms of tolvaptan-induced toxicity in HepG2 cells. Biochem. Pharmacol. 95, 324-336.
56. Yalcin, B. Flint, J. and Mott, R. (2005). Using progenitor strain information to identify quantitative trait nucleotides in outbred mice. Genetics 171, 673-681.
57. Yu, Y. Ping, J. Chen, H. Jiao, L. Zheng, S. Han, Z. G. Hao, P. and Huang, J. (2010). A comparative analysis of liver transcriptome suggests divergent liver function among human, mouse and rat. Genomics 96, 281-289.
58. Zhang, Z. Wang, W. and Valdar, W. (2014). Bayesian Modeling of Haplotype Effects in Multiparent Populations. Genetics 198, 139-156.